Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Pamiparib (Primary) ; Tamoxifen (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2024 Trial design evaluating the efficacy and toxicity of pamiparib and tamoxifen in ovarian cancer patients with biochemical recurrence during first-line PARPi maintenance therapy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jan 2023 New trial record